首页> 美国卫生研究院文献>Haematologica >Efficacy and safety of idelalisib in patients with relapsed rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

【2h】

Efficacy and safety of idelalisib in patients with relapsed rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

机译：依达黎西在复发性利妥昔单抗和烷化剂难治性滤泡性淋巴瘤患者中的疗效和安全性：一项2期研究的亚组分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Haematologica
作者
Gilles Salles; Stephen J. Schuster; Sven de Vos; Nina D. Wagner-Johnston; Andreas Viardot; Kristie A. Blum; Christopher R. Flowers; Wojciech J. Jurczak; Ian W. Flinn; Brad S. Kahl; Peter Martin; Yeonhee Kim; Sanatan Shreay; Matthias Will; Bess Sorensen; Madlaina Breuleux; Pier Luigi Zinzani; Ajay K. Gopal;
展开▼
作者单位

展开▼
年(卷),期 2017(102),4
年度 2017
页码 e156–e159
总页数 4
原文格式 PDF
正文语种
中图分类血液学检验;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study [J] . Gilles Salles, Stephen J. Schuster, Sven de Vos, Haematologica . 2017,第4期

机译：依达黎西在复发性利妥昔单抗和烷化剂难治性滤泡性淋巴瘤患者中的疗效和安全性：一项2期研究的亚组分析
2. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial [J] . Ken Ohmachi, Kensei Tobinai, Tomohiro Kinoshita, International journal of hematology . 2018,第5期

机译：ObInutuzumab在先前未经处理的滤泡淋巴瘤患者中的功效和安全性：在随机阶段III镓试验中招收日本患者的亚组分析
3. Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First-in-Human Study [J] . Caimi Paolo, Kahl Brad S., Hamadani Mehdi, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：ADCT-402（LONCESTUXIMAB TESIRINE），一种新型抗体药物缀合物，复发/难治性滤泡淋巴瘤和地幔细胞淋巴瘤的安全性和有效性：中期结果来自第1阶段首次研究
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Bortezomib plus rituximab versus rituximab in patients with high-risk relapsed rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial [O] . Pier Luigi Zinzani, Nuriet K Khuageva, Huaqing Wang, 2012

机译：硼替佐米联合利妥昔单抗与利妥昔单抗治疗高危复发未接受利妥昔单抗或利妥昔单抗敏感的滤泡性淋巴瘤的患者：一项3期随机试验的亚组分析
7. ELARA: A PHASE 2 TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN ADULT PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA [O] . M. Dickinson, L. Popplewell, A. Kolstad, 2019

机译：Elara：调查Tisagenlecleucel在成人耐火/复发卵泡淋巴瘤患者中的疗效和安全性

Efficacy and safety of idelalisib in patients with relapsed rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

著录项

相似文献

相关主题

期刊订阅